Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00049452 · ClinicalTrials.gov registry record · Phase 3
Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer
A Phase 3 study, sponsored by Herbert Irving Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
NCT00049452 is a Phase 3 study that has completed, run by Herbert Irving Comprehensive Cancer Center. The registered enrollment target is 120 participants.
The verdict
NCT00049452, a Phase 3 study, has completed, sponsored by Herbert Irving Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
Study Summary
RATIONALE: It is not yet known whether zoledronate is effective in preventing bone loss in premenopausal women who are receiving adjuvant chemotherapy after undergoing surgery for early stage breast cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of zoledronate in preventing bone loss in premenopausal women who are receiving chemotherapy after surgery for early stage breast cancer.
Interventions
- DRUG zoledronic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2001-12 |
| Est. Completion | 2008-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00049452
The ClinicalTrials.gov registry entry for NCT00049452 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Herbert Irving Comprehensive Cancer Center, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which zoledronic acid is the first listed.
NCT00049452 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00049452 about?
NCT00049452 is a clinical study titled "Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer". RATIONALE: It is not yet known whether zoledronate is effective in preventing bone loss in premenopausal women who are receiving adjuvant chemotherapy after undergoing surgery for early stage breast cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of zoledronate in prevent...
What is the current status of trial NCT00049452?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2001-12. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00049452?
The interventions under investigation include: zoledronic acid (DRUG).
Who is sponsoring clinical trial NCT00049452?
This trial is sponsored by Herbert Irving Comprehensive Cancer Center, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.